VEGF receptor kinase inhibitors (Novartis/Schering)

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug NameVEGF receptor kinase inhibitors (Novartis/Schering)
Drug Alias NameVatalanib derivatives (Novartis/Schering)NVP-AAD-777ZK-202664
ClassificationSmall molecules
Mechanisms of ActionVascular endothelial growth factor receptor modulatorsVascular endothelial growth factor receptor antagonistsAngiogenesis inhibitors +[4] 
TargetsVascular endothelial growth factor receptor
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Pharma AgBayer Schering Pharma AG
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A